Zobrazeno 1 - 10
of 343
pro vyhledávání: '"E. Anders Kolb"'
Autor:
Chia-Chin Wu, Licai Huang, Zhongting Zhang, Zhenlin Ju, Xingzhi Song, E. Anders Kolb, Wendong Zhang, Jonathan Gill, Min Ha, Malcolm A. Smith, Peter Houghton, Christopher L. Morton, Raushan Kurmasheva, John Maris, Yael Mosse, Yiling Lu, Richard Gorlick, P. Andrew Futreal, Hannah C. Beird
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Osteosarcoma is the most common primary bone malignancy in children and young adults, and it has few treatment options. As a result, there has been little improvement in survival outcomes in the past few decades. The need for models to test
Externí odkaz:
https://doaj.org/article/f8e627346ea440b7a5955c5d78e43866
Autor:
Kasey J. Leger, Michael J. Absalon, Biniyam G. Demissei, Amanda M. Smith, Robert B. Gerbing, Todd A. Alonzo, Hari K. Narayan, Betsy A. Hirsch, Jessica A. Pollard, Bassem I. Razzouk, Kelly D. Getz, Richard Aplenc, E. Anders Kolb, Bonnie Ky, Todd M. Cooper
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
IntroductionAnthracyclines are effective in treating acute myeloid leukemia (AML) but limited by cardiotoxicity. CPX-351, a liposomal daunorubicin and cytarabine, may provide therapeutic benefit with less cardiotoxicity. Acute changes in left ventric
Externí odkaz:
https://doaj.org/article/4f7d5c7ff98a44ee954f1d19f9442a1c
Autor:
Kelsey J. Cook, Victoria Grusauskas, Lucy Gloe, Benjamin Q. Duong, Renee C. Gresh, E. Anders Kolb, Manisha Bansal, Allison S. Bechtel, Ramamoorthy Nagasubramanian, Susan M. Kirwin, Kathryn V. Blake, Nathan D. Seligson
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 8, Pp 1352-1358 (2023)
Abstract The risk of severe adverse events related to thiopurine therapy can be reduced by personalizing dosing based on TPMT and NUDT15 genetic polymorphisms. However, the optimal genetic testing platform has not yet been established. In this study,
Externí odkaz:
https://doaj.org/article/fe5f039cb9ea4d6a8bd56e740944b7dd
Autor:
Kasey J. Leger, Nora Robison, Hari K. Narayan, Amanda M. Smith, Tenaadam Tsega, Jade Chung, Amber Daniels, Zhen Chen, Virginia Englefield, Biniyam G. Demissei, Benedicte Lefebvre, Gemma Morrow, Ilona Dizon, Robert B. Gerbing, Reena Pabari, Kelly D. Getz, Richard Aplenc, Jessica A. Pollard, Eric J. Chow, W. H. Wilson Tang, William L. Border, Ritu Sachdeva, Todd A. Alonzo, E. Anders Kolb, Todd M. Cooper, Bonnie Ky
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
BackgroundPediatric acute myeloid leukemia (AML) therapy is associated with substantial short- and long-term treatment-related cardiotoxicity mainly due to high-dose anthracycline exposure. Early left ventricular systolic dysfunction (LVSD) compromis
Externí odkaz:
https://doaj.org/article/b99055bf1d704eadae2a445572632039
Autor:
Benjamin J. Huang, Jenny L. Smith, Jason E. Farrar, Yi-Cheng Wang, Masayuki Umeda, Rhonda E. Ries, Amanda R. Leonti, Erin Crowgey, Scott N. Furlan, Katherine Tarlock, Marcos Armendariz, Yanling Liu, Timothy I. Shaw, Lisa Wei, Robert B. Gerbing, Todd M. Cooper, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Jeffrey Rubnitz, Jing Ma, Jeffery M. Klco, Xiaotu Ma, Todd A. Alonzo, Timothy Triche, Soheil Meshinchi
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Relapsed pediatric acute myeloid leukemia is associated with poor prognosis. Here, the authors use RNA-seq data from 1503 primary samples to create a combined transcriptional and cytomolecular signature to improve relapse risk prediction.
Externí odkaz:
https://doaj.org/article/25d98e54e2234ca19a9e20931766c2ae
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss , Pp 201-209 (2020)
Approximately 1%–2% of children with Down syndrome (DS) develop acute myeloid leukemia (AML) prior to age 5 years. AML in DS children (ML-DS) is characterized by the pathognomonic mutation in the gene encoding the essential hematopoietic transcript
Externí odkaz:
https://doaj.org/article/fd5d0a78aaea465fbb4034ac1d82ed03
Autor:
Erin L. Crowgey, Nitin Mahajan, Wing Hing Wong, Anilkumar Gopalakrishnapillai, Sonali P. Barwe, E. Anders Kolb, Todd E. Druley
Publikováno v:
BMC Medical Genomics, Vol 13, Iss 1, Pp 1-11 (2020)
Abstract Background Pediatric leukemias have a diverse genomic landscape associated with complex structural variants, including gene fusions, insertions and deletions, and single nucleotide variants. Routine karyotype and fluorescence in situ hybridi
Externí odkaz:
https://doaj.org/article/029a6cb2db584381a88e47b62bf2432e
Autor:
Fieke W. Hoff, Anneke D. van Dijk, Yihua Qiu, Chenyue W. Hu, Rhonda E. Ries, Andrew Ligeralde, Gaye N. Jenkins, Robert B. Gerbing, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Amina A. Qutub, Eveline S.J.M. de Bont, Terzah M. Horton, Steven M. Kornblau
Publikováno v:
Haematologica, Vol 107, Iss 10 (2022)
Pediatric acute myeloid leukemia (AML) remains a fatal disease for at least 30% of patients, stressing the need for improved therapies and better risk stratification. As proteins are the unifying feature of (epi)genetic and environmental alterations,
Externí odkaz:
https://doaj.org/article/ec910a7b013b405a849aaa5ec9509aa0
Autor:
Sonali P. Barwe, Anilkumar Gopalakrisnapillai, Nitin Mahajan, Todd E. Druley, E. Anders Kolb, Erin L. Crowgey
Publikováno v:
Genomics & Informatics, Vol 18, Iss 1 (2020)
Acute leukemia represents the most common pediatric malignancy comprising diverse subtypes with varying prognosis and treatment outcomes. New and targeted treatment options are warranted for this disease. Patient-derived xenograft (PDX) models are in
Externí odkaz:
https://doaj.org/article/eee48c9c0186465c9c42dd38b11b285a
Autor:
Jo Lynne Rokita, Komal S. Rathi, Maria F. Cardenas, Kristen A. Upton, Joy Jayaseelan, Katherine L. Cross, Jacob Pfeil, Laura E. Egolf, Gregory P. Way, Alvin Farrel, Nathan M. Kendsersky, Khushbu Patel, Krutika S. Gaonkar, Apexa Modi, Esther R. Berko, Gonzalo Lopez, Zalman Vaksman, Chelsea Mayoh, Jonas Nance, Kristyn McCoy, Michelle Haber, Kathryn Evans, Hannah McCalmont, Katerina Bendak, Julia W. Böhm, Glenn M. Marshall, Vanessa Tyrrell, Karthik Kalletla, Frank K. Braun, Lin Qi, Yunchen Du, Huiyuan Zhang, Holly B. Lindsay, Sibo Zhao, Jack Shu, Patricia Baxter, Christopher Morton, Dias Kurmashev, Siyuan Zheng, Yidong Chen, Jay Bowen, Anthony C. Bryan, Kristen M. Leraas, Sara E. Coppens, HarshaVardhan Doddapaneni, Zeineen Momin, Wendong Zhang, Gregory I. Sacks, Lori S. Hart, Kateryna Krytska, Yael P. Mosse, Gregory J. Gatto, Yolanda Sanchez, Casey S. Greene, Sharon J. Diskin, Olena Morozova Vaske, David Haussler, Julie M. Gastier-Foster, E. Anders Kolb, Richard Gorlick, Xiao-Nan Li, C. Patrick Reynolds, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock, Pichai Raman, David A. Wheeler, John M. Maris
Publikováno v:
Cell Reports, Vol 29, Iss 6, Pp 1675-1689.e9 (2019)
Summary: Accelerating cures for children with cancer remains an immediate challenge as a result of extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms evolving between diagnosis and relapsed disease, and li
Externí odkaz:
https://doaj.org/article/5a7054ef48fe4832b69df7b358c3a0d5